Caidya CEO Barbara Lopez Kunz explored the opportunities and complexities of integrating APAC into global clinical development programs in an interview with BioSpectrum Asia.
Published
Signal category
Presence & Recognition
Quote
“In a recent interview with BioSpectrum Asia Asia, Caidya CEO Barbara Lopez Kunz explores the opportunities and complexities of integrating APAC into global clinical development programs.”
— Caidya team
Company
Caidya
Adapting at the Speed of Science.
- Industry
- Biotechnology Research
- Location
- Raleigh, US
- Company size
- 734 employees
Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed in 2021 following the combination of leading CROs, dMed and Clinipace, Caidya has nearly 1,800 employees in more than 30 countries throughout the world.